Overboard: Alexis Borisy will have to limit director posts to stay on at Blueprint

Repeat biotech founder Alexis Borisy will have to give up at least two of his public board seats within a year, since the investor is no longer in compliance with Blueprint Medicines’ corporate policy.

For now, Blueprint is loosening its recently enacted rule that restricts its members to no more than four public board seats at a time so that Borisy can remain on the board. He co-founded the oncology and blood disorder company in 2011.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

2seventy bio, Bristol Myers stop late-stage Abecma study in multiple myeloma due to recruitment challenges

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 26, 2024

Tips to help keep feet healthy during summer and prevent athlete’s foot

As the days heat up and we head into the Summer, many of us suddenly seem to remember that the appendages at the end of

June 22, 2024

FDA grants ODD status to MDL-101 for LAMA2-CMD treatment

LAMA2-CMD is characterised by the absence of the LAMA2 protein, leading to severe, early-onset muscular dystrophy. Credit: Ines Nepo/Shutterstock. The US Food and Drug Administration

October 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.